Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2021-03-04 Director's Dealing
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-03-04 English
PRIMARY DOCUMENT
Director's Dealing
2021-03-04 English
PRIMARY DOCUMENT
Director's Dealing
2021-03-04 English
PRIMARY DOCUMENT
Director's Dealing
2021-03-04 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement for an at-the-market offering program, which is a financing activity. The document includes details about the sales agreement with SVB Leerink LLC for selling shares up to $200 million. This is a clear update on the company's capital raising activities. The document is not a full financial report, earnings release, or management discussion, but rather a specific announcement about financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is not a mere announcement of a report publication or a short notice.
2021-03-02 English
424B5
Capital/Financing Update Classification · 95% confidence The document is titled as a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It discusses the offering of ordinary shares up to $200 million, including details about the sales agreement with SVB Leerink LLC, underwriting commissions, and risk factors. The document is a detailed offering prospectus supplement related to a securities offering, which is a type of capital raising activity. It is not an annual report, earnings release, or any other financial report but rather a disclosure document for a capital market transaction. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 15,000 characters, indicating it is a full filing, not just an announcement or notice. Hence, the classification is CAP with high confidence.
2021-03-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.